Prime- and base-editing mouse models advance cancer research

The cancer research landscape is transforming by introducing novel mouse models utilising prime- and base-editing techniques. Yesterday, a News & Views in Nature Biotechnology summarised the findings of two recent studies that carefully examine the role of specific genetic variants in cancer.

By: Gorm Palmgren - Dec. 21, 2023
News

#CRISPRMED24

These advanced models present a significant leap over traditional genetically engineered mouse models and CRISPR methodologies. By enabling more accurate and efficient studies of single-nucleotide variants (SNVs) in cancer, these models open new avenues for understanding and combating this complex disease.

The prime-editing mouse model - developed at the Massachusetts Institute of Technology - stands out for its high editing efficiencies, particularly in lung and pancreatic organoids. This model facilitates in-depth exploration of drug-resistance mutations, a critical aspect in cancer treatment. Similarly, the base-editing model - developed at Weill Cornell Medicine - demonstrates its prowess in creating high-throughput organoid-based models for studying complex genetic variations.

The precision and efficiency of these models are crucial for delving deeper into the mechanisms of cancer development, spread, and identifying potential therapeutic targets. The advancements signal a new era in cancer research, where understanding the genetic underpinnings of cancer becomes more accessible and actionable.

Read the N&V by an Australian team led from the University of New South Wales here and find presentations of the two models here and here.

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagCMN BriefsHashtagMissing linksHashtagNewsHashtagCRISPR Therapeutics AG

News: Prime- and base-editing mouse models advance cancer research
News: Prime- and base-editing mouse models advance cancer research
CLINICAL TRIALS
Renal Cell Carcinoma, RCC, (NCT06245915)
Sponsors:
Arsenal Biosciences, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumors, (NCT06237881)
Sponsors:
M.D. Anderson Cancer Center
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Breast Cancer, BC, (NCT05812326)
Sponsors:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine